|
|
|
LifeScienceHistory.com - Check us out on Instagram
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Blueprint Medicines
| | | Phone: | (617) 374-7580 | Year Established: | 2011 | Ticker: | BPMC | Exchange: | NASDAQ | Main Contact: | Christina Rossi, CCO | | Other Contacts: | Tracey McCain, CLO Anthony (Andy) Boral, MD, Ph.D., CMO Marion Dorsch, Ph.D., CSO Jeffrey Albers, CEO Christopher Murray, Ph.D., Senior VP, Technical Operations Mike Landsittel, VP, Finance Christoph Lengauer, Ph.D., Executive VP
| | Company Description | Blueprint Medicines is driving the development of personalized, highly-selective cancer therapies that harness the growing understanding of the molecular blueprint of cancer. Using its powerful Insights-to-Validation™ Platform and proprietary chemical library, Blueprint Medicines is working to develop new therapeutic compounds and combination therapies that target the molecular aberrations that cause cancer and the emerging resistance mechanisms that make it increasingly difficult to treat. Founded in 2011 by a proven team of scientists and entrepreneurs with world-renowned expertise in the development of targeted cancer therapies, cancer genomics, and rational drug development, Blueprint Medicines is poised to realize the promise of the cancer data “revolution”: truly personalized therapies that improve outcomes and shift cancer to a manageable condition. | |
|
|
|
|
|